HER2-specific immunotoxins constructed based on single-domain antibodies and the improved toxin PE24X7

Naturally occurring antibodies devoid of light chains

C. Hamers‐Casterman, T. Atarhouch, Serge Muyldermans et al. · Nature · 1993 · 3.2K citations

Pharmacy, Biochemistry, Immunology +14

A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy

John Y. Li, Samuel R. Perry, Vanessa Muniz‐Medina et al. · Cancer Cell · 2016 · 390 citations · Full text

Medicine, Oncology, Pharmacology +14

Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer

Adi F. Gazdar, Venkatesh Kurvari, Arvind K. Virmani et al. · International Journal of Cancer · 1998 · 364 citations

Medicine, Genetics, Oncology +14

Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity

Yasuo Tsutsumi, Masanori Onda, Satoshi Nagata et al. · Proceedings of the National Academy of Sciences · 2000 · 217 citations

Medicine, Oncology, Pharmacology +15

Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb^®, GW572016) in an expanded panel of human normal and tumour cell lines

David W. Rusnak, Krystal J. Alligood, Robert J. Mullin et al. · Cell Proliferation · 2007 · 174 citations · Full text

Medicine, Oncology, Pharmacology +17